Takeda Pharmaceutical has entered into a strategic collaboration with NuBiyota, a Teaneck, New Jersey-based biological product company, for the development of gastrointestinal (GI) therapeutic products using NuBiyota’s Microbial Ecosystem Therapeutic platform.

Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed using NuBiyota’s microbiome platform for GI indications. NuBiyota will receive an upfront payment and is eligible for success-based development, regulatory, and commercial milestones as well as tiered royalties based on net sales. Further details of the agreement were not disclosed.

NuBiyota’s Microbial Ecosystem Therapeutic is a clinic-ready microbial consortia that provides an entry point for clinical evaluation of microbiome-based therapeutics. It is designed to enhance understanding of the role of microbiota in GI disease.

Source: Takeda Pharmaceutical